Clinical Trial Update: A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating multiple-dose BLU-5937 for chronic pruritus associated with atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Pruritus

Drugs mentioned

• BLU-5937 (BLU-5937)

Snippet

Sponsor: Bellus Health Inc. - a GSK company | Conditions: Chronic Pruritus, Atopic Dermatitis | Phase 2 | Status: COMPLETED